Pharmaceuticals

Peanut Allergy Treatment Market Analysis With Focus On Growth Potential And Future Outlook

May 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Peanut Allergy Treatment Market In 2026, And How Will Its Value Evolve By 2030?

The peanut allergy treatment market has experienced rapid expansion in recent years. It is forecast to grow from $0.5 billion in 2025 to $0.55 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.8%. This historical growth can be attributed to the rising prevalence of peanut allergies in children, the limited effectiveness of avoidance-only management, increased diagnosis of food allergies, strong reliance on epinephrine for emergency treatment, and growing awareness among healthcare professionals.

The peanut allergy treatment market size is projected to experience robust expansion over the coming years. This market is anticipated to reach $0.8 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.7%. The expected growth during the forecast period can be attributed to advancements in immunotherapy technologies, a rise in approvals for disease-modifying treatments, increasing demand for preventive allergy care, the expansion of biologics designed to target allergic pathways, and growing investment in food allergy research. Major trends predicted for the forecast period include the increasing adoption of oral immunotherapy for peanut desensitization, a growing utilization of epicutaneous immunotherapy patches, enhanced integration of biologic therapies in allergy treatment, the expansion of pediatric-focused peanut allergy treatments, and a greater emphasis on long-term allergy management solutions.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15888&type=smp

Which Key Factors Are Driving The Peanut Allergy Treatment Market Growth?

The future expansion of the peanut allergy treatment market is expected to be propelled by investments in research and development for allergy treatments. Research and development (R&D) investment refers to financial resources allocated by companies, organizations, or governments towards activities focused on innovation, product advancement, and technological progress. Such investment in allergy treatments is critical for advancing therapies for peanut allergies, as it fosters the creation of innovative immunotherapies and desensitization techniques. These advancements aim to reduce allergic reactions and improve the quality of life for individuals affected by peanut allergies. For example, in January 2024, the Victorian Government announced a strategic $12 million investment in Aravax, an Australia-based clinical-stage biotechnology company, to significantly advance global peanut allergy treatment. This funding is part of a broader $66 million round designated for developing Aravax’s innovative immunotherapy, PVX108. This initiative has secured Phase 2 trial approvals from both the U.S. Food and Drug Administration (FDA) and Australia’s Therapeutic Goods Administration (TGA), underscoring its potential worldwide public health impact. Thus, investment in research and development of allergy treatments is a key driver for the growth of the peanut allergy treatment market.

Which Segment Types Are Examined In The Peanut Allergy Treatment Market Segment Study?

The peanut allergy treatment market covered in this report is segmented –

1) By Drug Class: Antihistamines, Immunotherapies, Epinephrine, Other Drug Classes

2) By Route Of Administration: Injectable, Oral, Other Routes Of Administration

3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Other Distribution Channels

Subsegments:

1) By Antihistamines: Oral Antihistamines, Topical Antihistamines

2) By Immunotherapies: Oral Immunotherapy (OIT), Sublingual Immunotherapy (SLIT), Epicutaneous Immunotherapy (EPIT)

3) By Epinephrine: Epinephrine Auto-Injectors, Epinephrine Inhalers

4) By Other Drug Classes: Leukotriene Receptor Antagonists, Monoclonal Antibodies, Corticosteroids

Which Trends Are Shaping Growth In The Peanut Allergy Treatment Market?

Companies operating in the peanut allergy treatment market are concentrating on developing biologic therapies, such as anti-IgE monoclonal antibodies, to deliver more targeted and effective solutions for managing peanut allergies, thereby striving to enhance patient outcomes and quality of life. Anti-IgE monoclonal antibodies serve as a type of therapeutic agent designed to specifically target and neutralize immunoglobulin E (IgE) antibodies within the body. For instance, in February 2024, Novartis Pharmaceuticals Corporation, a Switzerland-based pharmaceutical company, obtained approval from the Food and Drug Administration (FDA) for Xolair (omalizumab). This medication is designed to mitigate allergic reactions, including anaphylaxis, in patients aged 1 year and older who have IgE-mediated food allergies. The approval was granted based on data from the NIH-sponsored Phase III OUtMATCH study, which indicated a notable improvement in food allergy tolerance among patients treated with Xolair compared to those who received a placebo.

Which Players Are Part Of The Competitive Landscape Of The Peanut Allergy Treatment Market?

Major companies operating in the peanut allergy treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Viatris Inc., Regeneron Pharmaceuticals Inc., Hikma Pharmaceuticals plc, ALK-Abelló A/S, Amneal Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc, Stallergenes Greer plc, kaleo Inc., Aquestive Therapeutics Inc., Vedanta Biosciences Inc., Aimmune Therapeutics Inc., AnaptysBio Inc., Alladapt Immunotherapeutics Inc., Aravax Pty Ltd, Intrommune Therapeutics Inc., IgGenix Inc., DBV Technologies SA, Camallergy Ltd., HAL Allergy Group, Prota Therapeutics Pty Ltd.

Get The Full Peanut Allergy Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/peanut-allergy-treatment-global-market-report

Which Geographic Region Dominates The Peanut Allergy Treatment Market?

North America was the largest region in the peanut allergy treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peanut allergy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Peanut Allergy Treatment Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/peanut-allergy-treatment-global-market-report

Browse Through More Reports Similar to the Global Peanut Allergy Treatment Market 2026, By The Business Research Company

Peanut Allergy Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/peanut-allergy-treatment-global-market-report

Allergy Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/allergy-treatment-global-market-report

Food Allergy Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/food-allergy-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795